CME/CE

This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

Over the past two decades, advances in disease biology and precision medicine have transformed the diagnosis and treatment of non–small cell lung cancer (NSCLC). Improved understanding of NSCLC molecular drivers has led to the development of targeted therapies and immunotherapies that have enhanced disease control, symptom management, and survival for selected patients. The treatment landscape for EGFR-mutated NSCLC continues to evolve rapidly, with therapies increasingly guided by molecular profiling and histology. As treatment options expand and become more complex, members of the oncology team must stay current on molecular testing, emerging therapies, and toxicity management to optimize patient outcomes.

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.